Introduction
Intracerebral experimental gliomas attract intravenously injected CD34
+ haematopoietic progenitor and stem cells (HPC). The underlying molecular pathways leading to the glioma tropism of HPC involve a transforming growth factor (TGF)-b-dependent signalling cascade regulating the release of stromal cell-derived factor (SDF)-1a/CXC chemokine ligand 12 (CXCL12) by glioma cells. CXCL12 interacts with the chemokine receptor CXCR4 on HPC. Further, matrix metalloproteinase 9 cleaves and thereby releases soluble Kit ligand (sKitL), which interacts with the receptor CD117 on HPC (Tabatabai et al., 2005) . Cerebral irradiation promotes the homing of HPC to the tumour bulk and to tumour satellites in vivo. Supernatants of irradiated or hypoxic glioma cells enhance HPC migration in vitro due to a TGF-b-dependent, hypoxia-inducible factor-1a (HIF-1a)-mediated induction of CXCL12 promoter activity in glioma cells (Tabatabai et al., 2006) . CXCL12 is also an important mediator for the attraction of mesenchymal stem cells to experimental gliomas (Nakamizo et al., 2005) . A systemic gradient of CXCL12 alone, however, does not explain the glioma-mediated attraction of intravenously injected HPC. Moreover, further insight into the mechanism of the glioma tropism is required for the design of a HPC-based cellular therapy that specifically targets gliomas.
The regional expression of endothelial adhesion molecules may contribute to the specificity of HPC homing towards gliomas. Similarities in the trafficking and homing of HPC and leucocytes to particular tissue sites arise. The diapedesis of leucocytes to sites of infection and inflammation is an important step in their recruitment. This process ensures appropriate innate and adaptive immunological responses. Adhesion molecules mediate rolling and arrest of leucocytes on the vessel wall as key steps prior to the transmigration across the endothelial layer (Millan et al., 2006; Nieminen et al., 2006) .
Adhesion is also critical for the interaction of HPC within the haematopoietic microenvironment in the bone marrow. Important mediators of this adhesive interaction include vascular cell adhesion molecule 1 (VCAM-1), platelet selectin (CD62P) and endothelial selectin (CD62E) Katayama et al., 2003) . CD62P is deposited in storage granules of platelets and endothelial cells. After activation, it is translocated to the surface (Bevilacqua et al., 1989) . VCAM-1 and CD62E are solely expressed on endothelial cells . In this study, we analysed the role of HPC adhesion to endothelial cells in the glioma tropism of HPC.
Material and Methods

Cell culture
Human adult HPC were isolated by anti-CD34 immunomagnetic microbeads (Bautz et al., 2001) . After informed consent, peripheral blood cells were obtained from healthy donors or patients with non-haematological malignancies during G-CSFinduced stem cell mobilization, according to the guidelines of the ethics committee of the University of Tübingen (project number 268/2003-LP). The human CD34 antigen is a reliable marker for identifying a small fraction of human bone marrow and peripheral blood mononuclear cells consisting of primitive uncommitted and pluripotent haematopoietic progenitor cells as well as haematopoietic stem cells (Andrews et al., 1986; Berenson et al., 1988; Terstappen et al., 1991; Van Epps et al., 1994; Gothot et al., 1998; Gao et al., 2001; Albo et al., 2004) . The source, generation and culture conditions of the cerebral vascular endothelial cell line SV-HCEC and the astrocytic cell line SV-FHAS have been described (Muruganandam et al., 1997) . Brain tumour endothelial cells (BTEC) were isolated from freshly resected human glioblastomas and characterized for their endothelial cell phenotype as described (Miebach et al., 2006) . Briefly, the tissue was minced, homogenized and digested enzymatically. The cells were separated by percoll gradient centrifugation. CD31-positive cells were isolated by magnetic beads (Dynal, Hamburg, Germany). Only passage 0-2 cells were used for the experiments. Human microvascular endothelial cells (HMEC) were purchased from Cascade Biologics (Invitrogen GmbH, Karlsruhe, Germany). All glioma cell lines were kindly provided by Dr N. de Tribolet (Lausanne, Switzerland). In contrast to other LN-229 sublines, LN-229 glioma cells cultured in our laboratory exhibit wild-type p53 status (Wischhusen et al., 2003) and are designated LNT-229. The generation of LNT-229 sublines stably depleted from TGF-b 1 to TGF-b 2 by RNA interference (LNT-229 siTGF-b 1,2 ) and the control cells (LNT-229 puro) has been described (Friese et al., 2004) . The following primary glioma cultures were used: T113, T159, derived from glioblastomas and T132, derived from an anaplastic astrocytoma. The primary human glioma cultures were established from samples with high tumour content (Bähr et al., 2003) . Supernatants of glioma cells (SN-G) were generated in serum-free medium (SFM): 1.5 million glioma cells were first seeded in serum-containing medium in T75 cell culture flasks. The medium was removed on the following day and the cells were washed three times with PBS. Seven millilitres SFM were added, 48 h later, supernatants were harvested. Supernatant was concentrated using a Centriplus centrifugal filter device YM-3 (3 kD cutoff, Millipore, Eschborn, Germany). Protein quantification was performed using the Bradford assay (BioRad, Munich, Germany).
Treatment of endothelial cells with SN-G was performed for 6, 12, 24, 48 or 96 h. Incubation of cells in hypoxia was performed at 37 C and 1% O 2 for 6, 12, 24, 48 or 96 h (Wick et al., 2002a) . Cells were irradiated at 2 or 8 Gy g-cell, Nordion, Kanata, CA, USA) and analysed at 6, 12, 24, 48 or 96 h thereafter (Wick et al., 2002b) . Recombinant TGF-b 2 and vascular endothelial growth factor (VEGF 165 ), neutralizing antibodies to VEGF (clone 26503) and VEGF-R2 (clone 89106) were purchased from R&D Systems (Wiesbaden-Nordenstadt, Germany). SD-208 was provided by Scios (Fremont, CA, USA) (Uhl et al., 2004) . siRNA pools targeting human TGF-b 1 , TGF-b 2 or VEGF containing four selected siRNA duplexes each with a modification pattern that addresses off-target effects caused by both strands (ON-TARGETplus SMARTpool) and the non-targeting control pool (ON-TARGETplus siCONTROL Non-targeting Pool) were designed by and purchased from Dharmacon (Lafayette, CO, USA). The pool of siRNA duplexes targeting TGF-b 1 had the following sense sequences:
0 . The siRNA duplexes targeting TGF-b 2 had the following sense sequences:
0 . The siRNA duplexes targeting VEGF had the following sense sequences: 5 0 -GCAGAAUCAUCACGAAGUG, 5 0 -CAACAAAUGUG AAUGCAGA, 5 0 -GGAGUACCCUGAUGAGAUC, 5 0 -GAUCAAAC CUCACCAAGGC. Lipophilic transfection was performed with Metafectene Pro (Biontex, Martinsried, Germany).
Transendothelial migration of HPC
Migration assays were performed in transwell plates (Costar, Cambridge, MA, USA) of 6.5 mm diameter with 5 mm pore filters. SV-HCEC, HMEC or BTEC were plated at 10 5 cells/transwell on filters coated with fibronectin. Non-adherent cells were removed after 24 h. The adherent cells were cultured for 48 h to obtain confluent endothelial monolayers. Confluency of the endothelial monolayers was confirmed by measuring permeability for albumin (Möhle et al., 1997 (Möhle et al., ,1998 Naiyer et al., 1999) . The monolayers were used unstimulated, stimulated with SN-G or after exposure to irradiation or hypoxia. Prior to the migration experiment, the monolayer was washed three times with PBS. The 10 5 CD34 + HPC in 200 ml SFM were added to the upper compartment. SFM, recombinant CXCL12 or SN-G were added to the lower compartment. In neutralization experiments, the SV-HCEC were pre-incubated for 4 h at 37 C with a-CD62E (R&D, clone BBIG-E4[5D11]) or a-VCAM-1 (R&D, clone BBIG-V1 [4B2]) or appropriate control antibodies. Migration was assessed at 37 C, 5% CO 2 for 16 h. Cells that had migrated to the lower compartment were quantified with the CyQuant Assay (Invitrogen, Karlsruhe, Germany).
Reporter assays
For dual luciferase/renilla assays (Dyer et al., 2000) 200 ng of the respective reporter constructs was cotransfected with 20 ng of pRL-CMV. pGL3b.CD62E contains the full-length promoter of CD62E (Nübel et al., 2004) . pNFkB-Luc contains a firefly luciferase gene that is especially designed for the detection of nuclear factor kappa B (NFkB) signal transduction pathway activity. It contains four copies of the NFkB consensus sequence fused to a TATA-like promoter region from the Herpes simplex virus thymidine kinase promoter. The binding of endogenous NFkB leads to induction of transcription and activation of the reporter gene in the transfected cells indicating transcriptional activity of NFkB. Ad-IkBM, containing the NFkB repressor, and the control Ad-Mock were kindly provided by Dr P. A. Baker (McGill University, Ottawa, Canada).
TransAM NFkB family
Nuclear extracts were prepared (Nuclear Extract Kit, Active Motif, Rixensat, Belgium) from SV-HCEC, HMEC or BTEC. Raji extracts, provided by the assay, served as positive control. Nuclear extracts from NIH3T3 fibroblasts served as negative control. The transcriptional activity of the NFkB family p50, p65, p52, c-Rel and RelB was analysed by the transcripton factor assay TransAM NFkB family (Active Motif) according to manufacturer's protocol. Briefly, this assay is based on an enzyme-linked immunosorbent assay (ELISA) format using 96-well plates coated with immobilized oligonucleotides containing the NFkB consensus site. The active form of NFkB contained in nuclear extracts of cells binds to the oligonucleotides. Primary antibodies recognizing epitopes on activated p50, p52, p65, c-Rel or RelB and HRP-conjugated secondary antibodies are used for the detection and quantification of active NFkB family members by spectrophotometry.
Immunoblot
Immunoblots were performed as described (Tabatabai et al., 2006) . The following antibodies were used: phospho-Smad 2 (Ser 465/467), total Smad 2 (Cell Signaling, Boston, MA, USA), NFkB p50 and p65 (Santa Cruz, CA, USA) and GAPDH (Chemicon, Billerica, MA, USA).
Enzyme-linked immunosorbent assay
The concentrations of VEGF, sCD62E, TGF-b 1 and TGF-b 2 in the supernatants were determined by Quantikine Immunoassays from R&D Systems. A sandwich ELISA was performed to measure the levels of phosphorylated VEGF-R2 and total VEGF-R2 in cell lysates (Duo Set IC, R&D Systems). The proliferation of cells was assessed by a cell proliferation biotrak ELISA system (GE Healthcare, Buckinghamshire, UK).
Flow cytometry
SV-HCEC, HMEC or BTEC were grown in 12-well plates either untreated or stimulated with the indicated supernatant, hypoxia or irradiation for 6, 12, 24, 48 or 96 h. Flow cytometry was performed with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) (Eisele et al., 2006) . The following antibodies (R&D Systems) were used: anti-human CD62E, VEGF-R2 and VCAM-1. Signal intensity was calculated by dividing mean fluorescence obtained with specific antibody divided by signal intensity obtained with the isotype control antibody (specific fluorescence index, SFI). anaplastic astrocytomas WHO grade III (n = 10) were also investigated. All samples from diffuse and anaplastic astrocytomas were taken from primary tumours prior to therapy. Among 120 glioblastoma samples, 88 were derived from primary and 32 from recurrent tumours. Shortly after surgical removal, all specimens were fixed with 4% formalin (pH 7.4) and subsequently embedded in paraffin followed by preparation as tissue microarray (Warth et al., 2007) . Further, 60 samples from 33 autopsy cases of a normal brain bank were added. Clinical data are summarized in Table 1 . The tumour and normal brain tissues were stained with H&E, mouse anti-human antibodies to CD31 (Clone JC70A, Dako Cytomation, Glostrup, Denmark, 51 mg/ml), goat anti-human CD62E antibodies (Clone BBA18, R&D Systems, diluted 1:50) or the respective isotype control antibodies.
Human tissue samples and tissue microarray
Animal studies
On day 0, 10 4 SMA-560 cells were stereotactically implanted into the right striatum of VM/Dk mice. On day 7, LSK were isolated from the bone marrow of VM/Dk mice as described (Tabatabai et al., 2005) . Briefly, femora and tibiae of VM/Dk mice were flushed with 2% FCS-containing PBS, erythrocytes were lysed, bone marrow cells were incubated for 60 min at 4 C with the lineage marker antibodies rat anti-mouse CD4, CD8a, CD45R/ B220, Gr-1, CD11b and TER119 (BD Biosciences Pharmingen, San Diego, CA, USA), then washed with PBS prior to the addition of pre-washed sheep anti-rat IgG magnetic beads (Dynabeads, Dynal, Biotech ASA, Oslo, Norway) at a 4 : 1 ratio of beads/cells. After 45 min, beads and attached cells were magnetically removed. The remaining lineage-depleted (lin -) cells were sorted with antiSca1 + beads by MACS (Miltenyi Biotech, Bergisch Gladbach, Germany). The check of purity by flow cytometry revealed that 55% of the isolated LSK expressed CD4, CD8, CD11b, B220 or Gr-1. LSK were between 95% and 98% positive for Sca1 and 499% positive for c-kit (BD Biosciences Pharmingen). The LSK were cultured with murine IL-3 (20 ng/ml), IL-6 (50 ng/ml) and SCF (50 ng/ml) (R&D Systems) over night. On day 8, neutralizing rat anti-mouse CD62E (BD Bioscience, clone 10E9.6) or control antibodies were bolus-injected intraperitoneally (200 ml) and intravenously (5 ml). Four hours later, PKH26 (Sigma-Aldrich, Taufkirchen, Germany) stained LSK were injected intravenously. On day 10, mice were sacrificed. From each experimental group, three brains were analysed by flow cytometry and three brains by histology. For flow cytometry, 5 mm 3 of the tumour-bearing as well as the contralateral hemisphere were dissociated in single cell suspension. For histology, 8 mm cryostat sections were stained with H&E and antibodies to vWF (Dako Cytomation) or CD62E (BD Biosciences). Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (Vectashield with DAPI, Vector Laboratories, Axxora GmbH, Loerrach, Germany).
Statistical analysis
Quantitative data were obtained for migration, ELISA, flow cytometry and reporter assays as indicated. Data are expressed as mean and SEM. Statistical significance was assessed by one-way ANOVA followed by Tukey's post hoc test (Excel, Microsoft, Seattle, WA, USA). The experiments reported here were performed at least three times in triplicate with similar results.
Results
Transendothelial HPC migration is enhanced after pretreatment of endothelial cells with SN-G
The molecular signature of endothelial cells depends on the environment. Endothelial cells from vessels within normal tissue are different from endothelial cells of vessels within inflamed or neoplastic tissue (Frenette et al., 1996b) . To simulate the conditioning of endothelial cells of vessels within glioblastoma tissue in vitro, we cultured cerebral endothelial cells (SV-HCEC) or HMEC in supernatant of LNT-229, LN-308, T113, T159 or T132 glioma cells. Further, we used BTEC from human glioblastoma specimens. HPC migrated through an untreated SV-HCEC-, HMEC (data not shown) and BTEC layer (Fig. 1) . The migration was significantly enhanced after the preincubation of all three types of endothelial cell layer with different SN-G. Pretreatment of the SV-HCEC, HMEC (data not shown) and BTEC with hypoxia and irradiation also increased the migration of HPC. In contrast, incubation with supernatant of the astrocytic cell line SV-FHAS (SN-FHAS) did not modulate transendothelial migration. Thus, SN-G, hypoxia or irradiation alter the characteristics of endothelial cells and hence promote the transendothelial migration of HPC.
SN-G induces the expression of CD62E on SV-HCEC and HMEC
To understand the increase in transendothelial HPC migration, we performed flow cytometry for the detection of VCAM-1 and CD62E on SV-HCEC, HMEC or BTEC either un-or pretreated with SN-G, irradiation or hypoxia. Untreated SV-HCEC, HMEC and BTEC constitutively expressed VCAM-1 at SFI values of 1.8, 1.7 and 1.9. The expression of VCAM-1 was not altered after pretreatment of the endothelial cells with SN-G, irradiation or hypoxia (data not shown). In contrast, CD62E was expressed on untreated BTEC but not on untreated SV-HCEC or HMEC. However, SN-G enhanced or induced the expression of CD62E as did hypoxia or irradiation (Fig. 2) . Pretreatment with VEGF 165 served as a positive control. was present in all neoplastic samples. CD62E strongly correlated with blood vessel morphology. Large vascular proliferations in glioblastoma samples showed the strongest CD62E immunoreactivity whereas smaller, more regular blood vessels found in the same tumours displayed a weaker CD62E staining intensity (Fig. 3) . There was no difference between CD62E expression in samples derived from primary or recurrent glioblastomas. A slight cytoplasmic CD62E staining was detected in tumour cells of most tumour samples. This prompted us to determine the concentration of soluble CD62E (sCD62E) in SN-G and in supernatants of endothelial cells in vitro by ELISA. Supernatant of BTEC harvested after 96 h contained sCD62E (70 AE 10 pg/ml) whereas SN-G and supernatant of untreated SV-HCEC and HMEC did not. In contrast, 96 h after stimulating SV-HCEC and HMEC with SN-G, sCD62E was detected in the supernatant of these endothelial cells (50-70 pg/ml). Thus, CD62E shedding and release of sCD62E may account for the apparent cytoplasmic staining observed in astrocytoma samples (Fig. 3) .
Enhanced migration of HPC through an SV-HCEC layer in vitro depends on CD62E
We next investigated the role of HPC adhesion to CD62E for transendothelial HPC migration through an SN-G-conditioned endothelial cell layer. We studied the transendothelial migration in the absence or presence of neutralizing antibodies to CD62E either with or without pretreatment of the endothelial cell layer. Neutralizing CD62E reduced the transendothelial HPC migration significantly (Fig. 4A, first panel) . (SN-GsiTGF-b), was reduced and neutralizing a-CD62E did not modulate HPC migration (Fig. 4A, second panel) . LN-308 cells inhibited the phosphorylation of Smad2 (Fig. 4B) indicating abrogation of TGF-b signalling. HPC migration through endothelial cells that had been pretreated with supernatant of these cells was accordingly reduced and neutralizing CD62E did not modulate the migration (Fig. 4A, third and fourth panel) .
Pre-irradiation of the endothelial cells resulted in an enhancement of transendothelial HPC migration (Fig. 1 ) that was also reduced by neutralizing CD62E antibodies (Fig. 4C) . In contrast, neutralizing VCAM-1 antibodies did not significantly reduce HPC migration through an untreated SV-HCEC-or BTEC or an SN-G-treated SV-HCEC layer (Table 2) . Exposure to hypoxia, irradiation, supernatant, neutralizing or control antibodies did not affect viability or proliferation of the endothelial cells or glioma cells (data not shown).
Homing of murine HPC to orthotopically implanted SMA-560 gliomas in vivo is reduced after neutralization of CD62E Subsequently, we investigated the role of CD62E for the glioma tropism of murine HPC in an orthotopic syngeneic glioma model in vivo. The 10 4 SMA-560 glioma cells were implanted into the right striatum of VM/Dk mice. On day 8, 10 6 PKH26-stained LSK cells were injected intravenously. Four hours before and 4 h after the injection of LSK, CD62E-neutralizing antibodies (six mice) or control antibodies (six mice) were bolus-injected both intraperitoneally and intratumourally in parallel in the same animals to block adhesion. On day 10, the brains were removed. Three brains per group were used for assessment by flow cytometry, three brains were analysed by histology. Injection of CD62E and control antibodies did not affect tumour morphology, tumour growth or vessel density as assessed by H&E or vWF staining (Fig. 5A) . The endothelial cells of tumour vessels expressed CD62E (Fig. 5A) . Fluorescence staining showed reduced numbers of PKH26-labelled cells within the SMA-560 gliomas after pretreatment with anti-CD62E antibodies (Fig. 5B) . Single cell suspensions of freshly removed samples of the SMA-560 gliomas or of the contralateral hemisphere were analysed by flow cytometry to quantify the numbers of PKH26-labelled cells. Co-treatment with anti-CD62E antibody strongly reduced the amount of PKH26-positive LSK in orthotopic SMA-560 gliomas (Fig. 5C ).
TGF-b signalling in glioma cells is required for SN-G-mediated induction of CD62E expression on SV-HCEC
We then characterized the time course of CD62E induction in SV-HCEC and HMEC. TNF-a treatment (100 U/ml) served as a positive control. This treatment resulted in high expression of CD62E by SV-HCEC (Fig. 6A) and HMEC ( Fig. 6B) after 6 h, then declining over the next 90 h. Similarly, treatment with VEGF 165 (40 ng/ml) resulted in high CD62E expression after 6 h, which was no more detectable 96 h after treatment. Culturing of SV-HCEC or HMEC in supernatant of the astrocytic cell line SV-FHAS did not induce CD62E expression. Treatment of SV-HCEC or HMEC with SN-G resulted in a maximum CD62E expression at 12 h ( Fig. 6A and B) .
Next, we analysed the role of TGF-b signalling for the induction of CD62E. The treatment of SV-HCEC with recombinant TGF-b 2 (10 ng/ml) did not induce CD62E expression (Fig. 7A) . We also collected supernatant of glioma cells that had been pretreated with the TGF-b receptor I kinase inhibitor, SD-208 (0.1 mmol/l and 1.0 mmol/l). SD-208 treatment blocked TGF-b signalling in LN-308, T113 and T132 cells (Fig. 7B) . The exposure of SV-HCEC to supernatant of these SD-208-treated glioma cells did not induce CD62E expression (Fig. 7A) . In accordance, exposure of SV-HCEC to SN-308 siTGF-b 1,2 ( Fig. 4A and B) did not induce CD62E (Fig. 7A) . Finally, we also treated LNT-229 siTGF-b 1,2 cells stably depleted from TGF-b 1 and TGF-b 2 (Friese et al., 2004) with recombinant TGF-b 2 (10 ng/ml) for 7 days to rescue TGF-b signalling in these glioma cells (Friese et al., 2004; Tabatabai et al., 2005; Eisele et al., 2006) . Supernatant from these cells again induced CD62E on SV-HCEC (Fig. 7A) . In contrast, the treatment of SV-HCEC with SN-G in the presence of SD-208, which abrogates TGF-b signalling pathway in SV-HCEC and HMEC (Fig. 7C) , did not influence the SN-G-mediated induction of CD62E. The exposure of endothelial cells to SN-GRT or SN-GHO led to the induction of CD62E, too. This effect was again prevented by SD-208 treatment of the glioma cells before harvesting the supernatant (data not shown).
The experiments involving the addition of recombinant TGF-b 2 or SD-208 indicate that (i) TGF-b signalling in glioma cells is required for the induction of CD62E on endothelial cells; but (ii) TGF-b signalling in SV-HCEC is 
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Induced CD62E expression on SV-HCEC is mediated by VEGF-R2 signalling
We next analysed the levels of VEGF, a candidate inducer of CD62E expression, in concentrated SN-Gp and SN-GsiTGF-b from cells treated with or without SD-208 or TGF-b 2 (Table 3) . VEGF release was reduced by abrogated TGF-b signalling. In contrast, addition of recombinant TGF-b 2 to LNT-229 siTGF-b 1,2 cells for 7 days before generation of supernatant restored VEGF levels in the supernatant. Further, irradiated and hypoxic SV-HCEC released increased levels of VEGF (Table 3) . SV-HCEC, HMEC and BTEC expressed the corresponding receptor VEGF-R2 (Fig. 8A) . Therefore, we analysed the role of VEGF/VEG-R2 signalling in endothelial cells for CD62E induction. Treatment of SV-HCEC, HMEC or BTEC with VEGF 165 , SN-G, hypoxia or irradiation increased the levels of phosphorylated VEGF-R2. NIH3T3 cells were used as negative controls (Fig. 8B) . The levels of total VEGF-R2 in untreated SV-HCEC (597 pg/ml) did not increase by exposure of SV-HCEC to VEGF 165 (590 pg/ml) or supernatant of LN-308 (572 pg/ml). Pretreatment with hypoxia, 2 Gy or 8 Gy, however, increased the levels of total VEGF-R2 in SV-HCEC (807, 992 and 2670 pg/ml). Similarly, the levels of total VEGF-R2 in untreated HMEC (664 pg/ml) was not increased by exposure to VEGF 165 (579 pg/ml), supernatant of LN-308 (660 pg/ml), whereas hypoxia (772 pg/ml), irradiation at 2 Gy (1222 pg/ ml) or 8 Gy (2982 pg/ml) led to elevated levels of total VEGF-R2 protein in HMEC. In BTEC, we detected levels of total VEGF-R2 in untreated (502 pg/ml), hypoxic (452 pg/ml) or irradiated cells (2 Gy: 459, 8 Gy 449 pg/ml). These data indicate that VEGF-R2 signalling activity in SV-HCEC, HMEC and BTEC is enhanced in response to SN-G, hypoxia or irradiation. Targeting of VEGF in glioma cells by siRNA pools led to a reduced VEGF release by LN-308 glioma cells or T113 primary cultures (Fig. 8C) . VEGF levels were also are reduced in supernatant of LN-308 siTGF-b 1,2 (Fig. 8C) and supernatant of LNT-229 after inhibition of TGF-b signalling (Table 3 ). The SN-G-mediated de novo expression of CD62E was prevented by VEGF gene silencing and by neutralizing VEGF or VEGF-R2 antibodies (Fig. 8D) . Further, the exposure of SV-HCEC to irradiation or SN-G, SN-GRT or SN-GHO supplemented with neutralizing a-VEGF and a-VEGF-R2 antibodies prevented CD62E induction (data not shown). Thus, (i) SN-G enhances VEGF-R2 signalling activity in endothelial cells; (ii) VEGF from SN-G, SN-GHO or SN-GRT is required for the SN-G-induced expression of CD62E in SV-HCEC; (iii) VEGF release from SV-HCEC is required for CD62E induction after exposure to hypoxia or irradiation.
Transcriptional activation of CD62E in endothelial cells is mediated by NFkB
The promoter of CD62E contains multiple NFkB-binding sites (Schindler et al., 1994) . We detected NFkB p65 and p50 in whole cell lysates of SV-HCEC (Fig. 9A) . Protein levels were not modulated by irradiation, hypoxia or exposure to SN-Gp, SN-GsiTGF-b or SN-GRT. Futher, we analysed the activation of the NFkB transcription family in nuclear extracts of BTEC, SV-HCEC and HMEC (Fig. 9B) . Raji extracts served as positive control, nuclear extracts from NIH3T3 cells were used as negative controls. The NFkB transcription factor family is activated in untreated endothelial cells. We next analysed the activity of p50 in nuclear extracts of endothelial cells after treatment with VEGF 165 or SN-G. TNF-a served as positive control (Fig. 9C) . VEGF 165 and SN-G further increased the transcriptional activity of p50 whereas treatment with supernatant of LN-308 siVEGF did not. In addition, we performed reporter assays with pNFkB-luc. This plasmid contains four copies of the NFkB consensus sequence and detects the transcriptional activity of NFkB. Treatment with TNF-a (100 U/ml) served as a positive control (Figs 9  and 10 ). The relative luciferase activity of pNFkB-luc in untreated BTEC, SV-HCEC and HMEC demonstrates the baseline transcriptional activity (Fig. 9D) in accordance with the data of the transAM assay (Fig. 9B and C) . 10 5 ) were added to the upper compartment of an endothelial cell monolayer-covered transwell insert. The monolayer was either untreated or stimulated with SN-G. SFM, CXCL12 (100 ng/ml) or supernatant of LNT-229 cells were added to the bottom wells. Relative transendothelial migration, i.e. migration related to basal migration towards SFM through the untreated monolayer, was determined 16 h later with or without neutralizing a-VCAM1-antibodies (mean, n = 3, SEM510%).
After exposure to TNF-a, VEGF 165 or SN-G, NFkB transcriptional activity significantly increased. Neutralizing antibodies to VEGF and VEGF-R2 reduced SN-G-induced NFkB transcriptional activity (Fig. 10) .
In parallel, we analysed the activity of the CD62E promoter by measuring the relative luciferase activity of pGL3basic.CD62E. In this plasmid, the reporter gene is driven by the CD62E promoter and indicates the activity of the CD62E promoter. We detected relative luciferase activity in untreated BTEC indicating a baseline promoter activity in accordance with the data from flow cytometry (Fig. 2) . In contrast, luciferase activity was absent in untreated SV-HCEC or HMEC, indicating a lack of CD62E promoter activity in this cell population (Fig. 9D ). After treatment with TNF-a, VEGF 165 or SN-G, however, the relative luciferase activity of pGL3.basic.CD62E increased (Fig. 10) . Irradiation with 2 Gy, 8 Gy or hypoxia also increased pGL3.basic.CD62E activity (data not shown). NFkB transcriptional activity and CD62E promoter activity were reduced by neutralizing a-VEGF and a-VEGF-R2 antibodies (Fig. 10) . To analyse whether NFkB transcriptional activity is required for CD62E promoter activity, we performed reporter assays after targeting NFkB by the NFkB-super-repressor Ad-IKBM. We transduced SV-HCEC with 100 MOI of Ad-IKBM. Ad-Mock served as control. Relative luciferase activity of pGL3.basic.CD62E in SV-HCEC was not induced by SN-G in the presence of the NFkB super repressor (Fig. 10) . These experiments place VEGF signalling and NFkB upstream of the transcriptional activation of CD62E in SV-HCEC. The presumptive signalling cascade leading to the induction of CD62E in SV-HCEC by SN-G, irradiation or hypoxia is summarized in Fig. 11 .
Discussion
Adult HPC migrate towards experimental gliomas. Therefore, this adult stem cell population might be a promising cellular vector for the delivery of therapeutic molecules to experimental gliomas. Before applying therapeutic approaches, however, the underlying molecular mechanisms of the glioma-mediated HPC attraction should be better understood. The objective in characterizing the glioma tropism of HPC is to achieve an optimal seeding of experimental gliomas with HPC. Adhesion molecules expressed on endothelial cells serve as keys to allow the entrance of circulating cells at specific tissue sites (Frenette et al., 1996a) . Bone marrow-and umbilical cord bloodderived CD34
+ HPC adhere to CD62E on bone marrow microvasculature (Najyer et al., 1999; Dimitroff et al., 2001; Hidalgo et al., 2002; Greenberg et al., 2000) . P-and E-selectin-deficient mice exhibit severe deficiencies in haematopoiesis (Frenette et al., 1996) . Intravital microscopy studies show that P-and E-selectin contribute to HPC rolling in the bone marrow microvasculature. Blocking both selectins and VCAM-1 inhibits the rolling interaction almost completely . Hidalgo et al. (2002) demonstrated by fluorescence intravital microscopy and homing assays in NOD/SCID mice that endothelial selectins are necessary for CD34 + HPC homing: rolling on bone marrow endothelium and retention in the bone marrow compartment are severely reduced in CD62E-deficient NOD/SCID mice. Thus, homing of HPC to the bone marrow is mediated by HPC interactions with multiple adhesion receptors. Among these, CD62E and VCAM-1 are expressed preferentially on endothelial cells. Therefore, we focused on investigating the possible contribution of CD62E and VCAM-1 to HPC glioma tropism.
CD62E expression in glioma-conditioned endothelial cells in vitro and in vivo
We used three different endothelial cell types: the cerebral endothelial cell line SV-HCEC (Muruganandam et al., 1997) , the endothelial cell line HMEC and BTEC (Miebach et al., 2006) . These endothelial cells constitutively express VCAM-1, but not CD62E. In the bone marrow microvasculature, CD62E and VCAM-1 are constitutively expressed (Schweitzer et al., 1996) . In most other tissues, however, CD62E is transcriptionally regulated and expressed on the surface after exposure to specific inflammatory stimuli (Bevilacqua et al., 1989) . We found CD62E expression on untreated BTEC. De novo CD62E expression by SV-HCEC and HMEC was induced after stimulation with SN-G, SN-GHO or SN-GRT, as well as treatment with hypoxia (Fig. 2) or irradiation. The constitutive VCAM-1 expression on the endothelial cells was not altered by these treatments. These results differ from studies with bone marrow microvasculature: total body irradiation of mice increased VCAM-1 expression, but the constitutive expression level of CD62E within the bone marrow microvasculature was unchanged (Mazo et al., 2002) . Having observed an SN-G-induced CD62E expression by SV-HCEC and HMEC in vitro, we analysed CD62E expression in situ. The endothelium of vessels within astrocytoma tissue of WHO grades II-IV highly expressed CD62E whereas CD62E staining was absent in normal brain (Fig. 3) . In addition to the well-defined CD62E staining of tumour endothelium, there was a diffuse extracellular and cytoplasmic staining in the neoplastic specimens. This might indicate the shedding of CD62E and the presence of the soluble form of CD62E (Oh et al., 2007) . In that regard, we also detected sCD62E in supernatant of stimulated SV-HCEC, HMEC and in supernatant of untreated BTEC in vitro.
CD62E is one mediator of the glioma-mediated HPC attraction in vitro and in vivo
The transendothelial migration of HPC was significantly diminished in the presence of neutralizing CD62E antibodies (Fig. 4) whereas neutralizing VCAM-1 antibodies had no such effect. In vivo, administration of a CD62E-blocking antibody prevented the accumulation of PKH26-positive LSK in orthotopic SMA-560 gliomas (Fig. 5) , indicating that CD62E is required for the glioma tropism of LSK in vivo. In a model of chronic kidney disease, Gong et al. (2006) demonstrated de novo CD62E expression in renal vascular endothelium mediating leucocyte adhesion. The bolus injection of neutralizing CD62E antibodies diminished interstitial inflammation and macrophage sequestration in the kidney in vivo. Recently, Nishiwaki et al. (2007) demonstrated a crucial role for CD62E in the interaction between circulating endothelial progenitor cells and vessel Brain (2008) , 131, 2579^2595 2591 endothelium in the mouse hind-limb ischaemia paradigm. Oh and colleagues (2007) demonstrated that CD62E is a pivotal molecule for endothelial progenitor cell homing to the ischaemic site and for vasculogenesis in an ischaemic limb model. Based on these data, a novel cell-based therapy for ischaemic atherosclerosis might be designed.
CD62E-induction mediates glioma tropism of HPC
SN-G-mediated induction of CD62E requires TGF-b signalling in glioma cells and VEGF/VEGF-R2 signalling in endothelial cells
We next investigated the molecular mechanism mediating the de novo expression of CD62E in SV-HCEC or HMEC.
Culturing of SV-HCEC with SN-GsiTGF-b did not induce CD62E expression (Fig. 7) . HPC migration through an SNGsiTGF-b-treated SV-HCEC layer was not altered by neutralizing a-CD62E. The reduction of relative HPC migration (Fig. 4A ) observed after pretreating SV-HCEC with SN-GsiTGF-b can be explained by the lack of CD62E expression (Fig. 7) . Based on this observation, we analysed the role of TGF-b signalling in the glioma-mediated induction of CD62E. When TGF-b signalling was inhibited in LNT-229 glioma cells before supernatant collectioneither by SD-208 or by siRNA-these supernatants did not induce CD62E expression (Fig. 7) . Inhibition of TGF-b signalling in SV-HCEC or HMEC by SD-208, however, did not modulate SN-G-mediated CD62E induction. Further, treatment of SV-HCEC with recombinant VEGF also mediates the irradiation-or hypoxia-induced de novo expression of CD62E.
